De Burlo Group’s NeuBase Therapeutics, Inc. Common Stock NBSE Stock Holding History

De Burlo Group’s Portfolio NBSE Stock Details NBSE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2015 Q3	–	Sell	-33	Closed	-$32K	–	112
2015 Q2	$32K	Sell	33 -370	-92%	-$399K	0.01%	104
2015 Q1	$409K	Buy	+403	New	+$1.33M	0.08%	87

Other funds holding NBSE

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

KCM

Knoll Capital Management Miami, Florida $180M AUM 66.11% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

SIP

Stoneridge Investment Partners Radnor, Pennsylvania $138M AUM 7.66% 1-Year Est. Return

PNC Financial Services Group Pittsburgh, Pennsylvania $173B AUM 20.72% 1-Year Est. Return

GBA

Garrison Bradford & Associates New York $88.4M AUM 15.86% 1-Year Est. Return

Hoxton Financial Shepherdstown, West Virginia $194M AUM 6.21% 1-Year Est. Return

De Burlo Group's NBSE Position: Q3 2015 in Review

De Burlo Group sold out of NeuBase Therapeutics, Inc. Common Stock (NBSE) in Q3 2015, closing a stake of 33 shares — an estimated $32K sold.

De Burlo Group first reported a position in NBSE in Q1 2015 and held it in 2 quarters. The position peaked at $409K in Q1 2015. 47 funds tracked by Wall St. Rank hold NBSE as of Q3 2015.

De Burlo Group reported no remaining NeuBase Therapeutics, Inc. Common Stock position as of Q3 2015 after selling out during the quarter.
De Burlo Group sold 33 NeuBase Therapeutics, Inc. Common Stock shares in Q3 2015, an estimated $32K.
De Burlo Group first reported a position in NeuBase Therapeutics, Inc. Common Stock in Q1 2015 and held it in 2 quarters.
De Burlo Group's NeuBase Therapeutics, Inc. Common Stock position peaked at $409K in Q1 2015.
47 funds tracked by Wall St. Rank held NeuBase Therapeutics, Inc. Common Stock as of Q3 2015.

Based on De Burlo Group's 13F filing for Q3 2015, filed 5 Nov 2015.